Tobira Therapeutics to Host Analyst and Investor Day on April 4, 2016

SOUTH SAN FRANCISCO, Calif., March 28, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, will host a live webcast in conjunction with its Analyst and Investor Day on Monday, April 4, 2016 at 12:30 p.m. ET in New York City.

Tobira's chief executive officer, Laurent Fischer, MD, and chief medical officer, Eric Lefebvre, MD, will be joined by guest speakers Arun J. Sanyal, MD, Virginia Commonwealth University, and Bertus Eksteen, MBChB, FRCP, PhD, University of Calgary, to discuss cenicriviroc and other novel therapies under development for NASH and primary sclerosing cholangitis.

To view and listen to the webcast, please visit Tobira's website at http://ir.tobiratx.com. Visitors will also be able to view and listen to an archive of the webcast found in the Investor Relations section of http://www.tobiratx.com/. The archive will be available for 30 days following the event.

For more information on the Investor Day, please refer to contact information within this press release.

About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and as an adjunctive therapy to standard of care in HIV. Learn more about Tobira at www.tobiratx.com.

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2016 Tobira Therapeutics, Inc. All Rights Reserved.

Tobira Investor & Media Contact:
Ian Clements, PhD
+1 (650) 351-5013
[email protected]

Canale Communications Media Contact:
Pam Lord
+1 (619) 849-6003
[email protected]

SOURCE Tobira Therapeutics, Inc.

Related Links

http://www.tobiratx.com